Management of venous thromboembolism in patients with cancer

J. J. López-Núñez, J. Trujillo-Santos, M. Monreal

Research output: Contribution to journalReview articleResearchpeer-review

10 Citations (Scopus)


© 2018 International Society on Thrombosis and Haemostasis Current guidelines for anticoagulant therapy do not so far suggest any form of differentiated approach to cancer patients with venous thromboembolism (VTE). This review article provides an overview of the published literature in cancer patients with VTE, mostly using data from the RIETE registry. Our findings provide some insights into what factors may be used to guide physicians in adapting recommended anticoagulant regimens to the individual patient, as oncologists are increasingly doing with cancer treatments. For instance, patients presenting with deep vein thrombosis (DVT) alone might benefit from curtailing treatment intensity as anticoagulant therapy progresses. The site of cancer also needs to be considered. In patients with incidental PE or splanchnic vein thrombosis, we should be more cautious before prescribing anticoagulant therapy. The optimal duration of anticoagulant therapy is unknown.
Original languageEnglish
Pages (from-to)2391-2396
JournalJournal of Thrombosis and Haemostasis
Issue number12
Publication statusPublished - 1 Dec 2018


  • anticoagulant therapy
  • bleeding
  • cancer
  • death
  • recurrences
  • venous thromboembolism


Dive into the research topics of 'Management of venous thromboembolism in patients with cancer'. Together they form a unique fingerprint.

Cite this